Influence of etiology on heart failure with preserved systolic function mortality in a population with high prevalence of chagas Cardiomyopathy;Influencia de la etiología sobre la mortalidad en la insuficiencia cardíaca con función sistólica preservada en una población con alta prevalencia de cardiopatía chagásica

Revista Argentina de Cardiologia

Volumn 81, Issue 3, 2013, Pages 246-250

  Dos Reis, Francisco Borges ^a   Fernándes, André M ^a   De Andrade, Gustavo M ^a   Bitencourt, Almir ^a   Neves, Flavia ^a   Franca, Víctor H ^a   Macedo, Cristiano ^a   Cruz, Cristiano ^a   Braga, Julio ^a   Aras, Roque ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Chagas disease; Diastolic heart failure; Heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; CHAGAS DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PROSPECTIVE STUDY; SYSTOLIC DYSFUNCTION; SYSTOLIC HYPERTENSION; TELECONSULTATION;

EID: 84880788233     PISSN: 00347000     EISSN: 18503748     Source Type: Journal    
DOI: 10.7775/rac.es.v81.i3.1417     Document Type: Article

References (29)

1. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, et al. I-Preserve Investigators. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010;121:1393-1405. http://doi.org/fnzkcm
2. Mesquita ET, Socrates J, Rassi S, Villacorta H, Mady C. Heart failure with preserved systolic function. Arq Bras Cardiol 2004;82:494-500. http://doi.org/fhb4x9
3. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-327. http://doi.org/dc7t24
4. Aurigemma GP. Diastolic heart failure a common and lethal condition by any name. N Engl J Med 2006;355:308-310.http://doi.org/bbx6vd
5. Shammas RL, Khan NU, Nekkanti R, Movahed A. Diastolic heart failure and left ventricular diastolic dysfunction: what we know, and what we don't know! Int J Cardiol 2007;115:284-292.http://doi.org/c74s7d
6. Punukollu G, Gowda RM, Khan IA, Navarro VS, Vasavada BC. Clinical aspects of the Chagas' heart disease. Int J Cardiol 2007;115:279-283.http://doi.org/dq2ft6
7. Human Experimentation: Code of Ethics of W.M.A. Br Med J 1964;2:177.
8. Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 2005;11:576-585.http://doi.org/bjk44b
9. Philbin EF, Rocco TA Jr, Lindenmuth NW, Ulrich K, Jenkins PL. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 2000;109:605-613. http://doi.org/c6x5rq
10. Varela-Roman A, Gonzalez-Juanatey JR, Basante P, Trillo R, Garcia-Seara J, Martinez-Sande JL, et al. Clinical characteristics and prognosis of hospitalised in patients with heart failure and preserved or reduced left ventricular ejection fraction. Heart 2002;88:249-254. http://doi.org/c868zx
11. Ansari M, Alexander M, Tutar A, Massie BM. Incident cases of heart failure in a community cohort: importance and outcomes of patients with preserved systolic function. Am Heart J 2003;146:115-120. http://doi.org/b7dzbq
12. Masoudi FA, Havranek EP, Smith G, Fish RH, Steiner JF, Ordin DL, et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003;41:217-223. http://doi.org/fkbtcv
13. Ilksoy N, Hoffman M, Moore RH, Easley K, Jacobson TA. Comparison of African-American patients with systolic heart failure versus preserved ejection fraction. Am J Cardiol 2006;98:806-808. http://doi.org/fpz8gg
14. Regitz-Zagrosek V, Brokat S, Tschope C. Role of gender in heart failure with normal left ventricular ejection fraction. Prog Cardiovasc Dis 2007;49:241-251. http://doi.org/brdrr5
15. Badano LP, Albanese MC, De Biaggio P, Rozbowsky P, Miani D, Fresco C, et al. Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction. J Am Soc Echocardiogr 2004;17:253-261. http://doi.org/ffvxwk
16. Lewis EF, Lamas GA, O'Meara E, Granger CB, Dunlap ME, McKelvie RS, et al; for the CHARM Investigators. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail 2007;9:83-91. http://doi.org/ffmzvp
17. Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, et al. Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005;112:3738-3744. http://doi.org/bvdzk9
18. Ahmed A, Perry GJ, Fleg JL, Love TE, Goff DC Jr, Kitzman DW. Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis. Am Heart J 2006; 152:956-966. http://doi.org/c3cm7g
19. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-9. http://doi.org/b52prg
20. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-269. http://doi.org/dpg8fd
21. Varadarajan P, Pai RG. Prognosis of congestive heart failure in patients with normal versus reduced ejection fractions: results from a cohort of 2,258 hospitalized patients. J Card Fail 2003;9:107-112. http://doi.org/fw5cc7
22. Varela-Roman A, Grigorian L, Barge E, Bassante P, de la Pena MG, Gonzalez-Juanatey JR. Heart failure in patients with preserved and deteriorated left ventricular ejection fraction. Heart 2005;91:489-494. http://doi.org/bmcf44
23. Cianciulli TF, Lax JA, Saccheri MC, Papantoniou A, Morita LA, Prado NG, et al. Early detection of left ventricular diastolic dysfunction in Chagas' disease. Cardiovasc Ultrasound 2006;4:18. http://doi.org/c5wjk2
24. Mady C, Ianni BM, Arteaga E, Salemi VM, de Carvalho Frimm C. Maximal functional capacity in patients with Chagas' cardiomyopathy without congestive heart failure. J Card Fail 2000;6:220-224. http://doi.org/ddnhqk
25. Mady C, Cardoso RHA, Pereira-Barretto AC, da Luz PL, Bellotti G, Pileggi F. Survival and predictors of survival in patients with congestive heart failure due to Chagas' cardiomyopathy. Circulation 1994;90:3098-3102. http://doi.org/kd3
26. Rassi A Jr, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med 2006;355:799-808. http://doi.org/dkz2g8
27. Hernandez G, Anguita M, Ojeda S, Duran C, Rodriguez A, Ruiz M, et al. Heart failure with preserved ejection fraction. Effect of etiology on prognosis. Rev Esp Cardiol 2006;59:346-351.
28. Freitas HF, Chizzola PR, Paes AT, Lima AC, Mansur AJ. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease. Int J Cardiol 2005;102:239-247. http://doi.org/fwjd9k
29. de Campos Lopes CB, Yamada AT, Araujo F, Pereira Barreto AC, Mansur AJ. Socioeconomic factors in the prognosis of heart failure in a Brazilian cohort. Int J Cardiol 2006;113:181-187. http://doi.org/c7269n